How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,079 results for

cephalosporin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Susceptibility of imipenem-susceptible but meropenem-resistant Enterobacteriaceae carrying <i>bla</i><sub>IMP-6</sub> to various antibacterials including siderophore cephalosporin, cefiderocol. Full Text available with Trip Pro

Susceptibility of imipenem-susceptible but meropenem-resistant Enterobacteriaceae carrying blaIMP-6 to various antibacterials including siderophore cephalosporin, cefiderocol. 28438934 2019 01 28 2019 01 28 1098-6596 61 7 2017 07 Antimicrobial agents and chemotherapy Antimicrob. Agents Chemother. Susceptibility of Imipenem-Susceptible but Meropenem-Resistant bla IMP-6 -Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol

2017 Antimicrobial Agents and Chemotherapy

142. Antibiotic prophylaxis is associated with subsequent resistant infections in children with an initial extended-spectrum cephalosporin-resistant <i>Enterobacteriaceae</i> infection. Full Text available with Trip Pro

Antibiotic prophylaxis is associated with subsequent resistant infections in children with an initial extended-spectrum cephalosporin-resistant Enterobacteriaceae infection. The objective of this study was to assess the association between previous antibiotic use, particularly long-term prophylaxis, and the occurrence of subsequent resistant infections in children with index infections due to extended-spectrum-cephalosporin-resistant Enterobacteriaceae We also investigated (...) the concordance of the index and subsequent isolates. Extended-spectrum-cephalosporin-resistant Escherichia coli and Klebsiella spp. isolated from normally sterile sites of patients aged <22 years were collected along with associated clinical data from four freestanding pediatric centers. Subsequent isolates were categorized as concordant if the species, resistance determinants, and fumC-fimH (E. coli) or tonB (Klebsiella pneumoniae) type were identical to those of the index isolate. In total, 323 patients

2017 Antimicrobial Agents and Chemotherapy

143. Cephalosporins

Cephalosporins USE OF CEPHALOSPORINS IN PREGNANCY 0344 892 0909 USE OF CEPHALOSPORINS IN PREGNANCY (Date of issue: June 2017 , Version: 3.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The cephalosporins (commonly used include: cefaclor (...) , cefadroxil, cefalexin, cefixime, cefotaxime, cefpodoxime, cefradine, ceftazidime, ceftriaxone and cefuroxime) are a class of β-lactam antibiotics originally derived from the Acremonium fungus. Cephalosporins are broad-spectrum antibacterial agents used in the treatment of respiratory tract infections, otitis media, skin and soft tissue infections, urinary tract infections, sexually transmitted infections, septicaemia, meningitis, peritonitis, endocarditis, and in the prophylaxis of postoperative

2014 UK Teratology Information Service

144. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. (Abstract)

IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. Studies regarding the cross-reactivity and tolerability of alternative cephalosporins in large samples of subjects with an IgE-mediated hypersensitivity to cephalosporins are lacking.We sought to evaluate the possibility of using alternative cephalosporins in subjects with cephalosporin allergy who especially require them.One hundred two subjects with immediate reactions (...) to cephalosporins and positive skin test results to the responsible drugs underwent serum specific IgE assays with cefaclor and skin tests with different cephalosporins. Subjects were classified in 4 groups: group A, positive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group B, positive responses to aminocephalosporins; group C, positive responses to cephalosporins other than those belonging to the aforementioned groups; and group D, positive responses

2015 Journal of Allergy and Clinical Immunology

145. Third Generation Anti-Pseudomonal Cephalosporins

Third Generation Anti-Pseudomonal Cephalosporins Third Generation Anti-Pseudomonal Cephalosporins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Third Generation Anti-Pseudomonal Cephalosporins Third Generation Anti-Pseudomonal Cephalosporins Aka: Third Generation Anti-Pseudomonal Cephalosporins , Ceftazidime From Related Chapters II. Coverage Pseudomonas (Main indication) poorly covered No coverage III. Preparations: Ceftazidime (Fortaz) Adult: 1-2 grams IM or IV every 8 to 12 hours Child: 30-50 mg/kg IV every 8 hours IV. Disadvantages Most expensive Limited spectrum Images: Related links to external sites (from Bing) These images

2018 FP Notebook

146. Third Generation Broad-Spectrum Cephalosporins

Third Generation Broad-Spectrum Cephalosporins Third Generation Broad-Spectrum Cephalosporins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Third Generation Broad-Spectrum Cephalosporins Third Generation Broad-Spectrum Cephalosporins Aka: Third Generation Broad-Spectrum Cephalosporins , Third Generation Cephalosporins , Ceftriaxone , Ceftizoxime , Cefotaxime , Cefpodoxime , Cefixime , Claforan , Rocephin , Vantin From Related Chapters II. Mechanism: Spectrum of Activity Less activity than Better activity than Better activity than No Pseudomonas activity III. Preparations: Oral agents Cefixime (Suprax) Adult Standard: 400 mg PO

2018 FP Notebook

147. Second Generation Broad-spectrum Cephalosporins

Second Generation Broad-spectrum Cephalosporins Second Generation Broad-spectrum Cephalosporins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Second Generation Broad-spectrum Cephalosporins Second Generation Broad-spectrum Cephalosporins Aka: Second Generation Broad-spectrum Cephalosporins , Second Generation Cephalosporins , Cefuroxime , Loracarbef , Cefprozil , Lorabid , Cefzil , Ceftin From Related Chapters II. Coverage III. Indications Respiratory tract infections IV. Preparations Loracarbef (Lorabid) Adult: 200 to 400 mg po bid Child : 30 mg/kg/day divided bid Other infections: 15 mg/kg/day divided bid Directions Take more

2018 FP Notebook

148. Second Generation Anti-anaerobe Cephalosporins

Second Generation Anti-anaerobe Cephalosporins Second Generation Anti-anaerobe Cephalosporins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Second Generation Anti-anaerobe Cephalosporins Second Generation Anti-anaerobe Cephalosporins Aka: Second Generation Anti-anaerobe Cephalosporins , Cefoxitin , Cefotetan , Cefamandole From Related Chapters II. Coverage III. Indications Abdominal Surgery prophylaxis Colorectal surgery prophylaxis IV. Coverage Cefoxitin (Mefoxin) 1-2 grams IM or IV every 6-8 hours Cefotetan (Cefotan) 1-2 grams IM or IV every 12 hours Cefamandole V. Downsides Poor overall activity Expensive Images: Related

2018 FP Notebook

149. First Generation Cephalosporins

First Generation Cephalosporins First Generation Cephalosporins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 First Generation (...) Cephalosporins First Generation Cephalosporins Aka: First Generation Cephalosporins , Cephalexin , Cefazolin , Cefadroxil , Keflex , Duricef , Ancef From Related Chapters II. Indications Effective alternative to s Covers Clinical Conditions Not indicated for III. Mechanism: Activity Spectrum Good Coverage Modest covered IV. Preparations: Oral Directions May take with or without food Cephalexin (Keflex) Adult: 250 to 500 mg PO qid Child : 75 to 100 mg/kg/day divided qid Standard Dose: 25 to 50 mg/kg/day

2018 FP Notebook

150. Cephalosporin

Cephalosporin Cephalosporin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Cephalosporin Cephalosporin Aka: Cephalosporin From (...) Related Chapters II. General Spectrum changes from first to third generation First ration: Better coverage Third ration: Better coverage III. Contraindications Drug allergy to other Cephalosporin Type I to a Less than 10% of those who report actually have a Cross reactivity was originally over-estimated as high as 10% in the 1960s Attributed to cross contamination from co-production of Cephalosporins and s in the same factory has only an overall 1-2% risk of cross-reactivity with Cephalosporins

2018 FP Notebook

151. A protocol for a systematic review and meta-analysis of the health and healthcare system burden due to human Escherichia coli infections resistant to third/fourth/fifth generation cephalosporins or quinolones, or with multidrug resistance

A protocol for a systematic review and meta-analysis of the health and healthcare system burden due to human Escherichia coli infections resistant to third/fourth/fifth generation cephalosporins or quinolones, or with multidrug resistance Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration

2018 PROSPERO

152. Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia: A Propensity-Score Adjusted Retrospective Study. Full Text available with Trip Pro

Comparable Effectiveness of First Week Treatment with Anti-Staphylococcal Penicillin versus Cephalosporin in Methicillin-Sensitive Staphylococcus aureus Bacteremia: A Propensity-Score Adjusted Retrospective Study. The objective was to compare the prognostic impact of first week treatment with anti-staphylococcal penicillin (ASP) versus cephalosporin in methicillin-sensitive Staphylococcus aureus bacteremia (MS-SAB). Altogether 580 patients were retrospectively followed and categorized according (...) to first week treatment; 84% (488) received ASP (cloxacillin) and 16% (92) cephalosporin (cefuroxime or ceftriaxone). SAB management was optimized with formal bedside infectious disease specialist consultation in 88%, deep infection foci diagnosed in 77% and adjunctive rifampicin therapy given to 61% of patients. The total case fatality in 580 patients was 12% at 28 days and 18% at 90 days. When comparing effectiveness of first week ASP versus cephalosporin treatment there were no significant

2016 PLoS ONE

153. A systematic review on the clinical significance of quinolone-resistant and third-generation cephalosporin- resistant non-typhoidal Salmonella in humans of any age

A systematic review on the clinical significance of quinolone-resistant and third-generation cephalosporin- resistant non-typhoidal Salmonella in humans of any age Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO

154. Adverse events in patients taking cephalosporins versus placebo for any indication [Cochrane protocol]

Adverse events in patients taking cephalosporins versus placebo for any indication [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

155. Adverse events in patients taking cephalosporins versus placebo for any indication [Cochrane Protocol]

Adverse events in patients taking cephalosporins versus placebo for any indication [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

156. Anaphylactic Cross-Reactivity Between Penicillin and Cephalosporin

Anaphylactic Cross-Reactivity Between Penicillin and Cephalosporin UTCAT848, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Minimal Risk Of Severe Type 1 Hypersensitivity Reaction To Third Generation Cephalosporin In Patients Who Experience Type 1 Hypersensitivity Reaction And Allergy To Penicillin Clinical Question Do patients who experience a severe type 1 hypersensitivity reaction to penicillin and demonstrate (...) an allergy to cephalosporin experience a severe type 1 hypersensitivity reaction to the cephalosporin? Clinical Bottom Line It appears that patients who have a severe type 1 hypersensitivity reaction to penicillin do not have an increased risk of anaphylaxis to cephalosporins. This evidence may be skewed however by adherence to the recommendation not to give cephalosporins to individuals with a history of penicillin anaphylaxis. (See Comments on the CAT below) Best Evidence (you may view more info

2011 UTHSCSA Dental School CAT Library

157. Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF and ompC in Enterobacter cloacae that are highly resistant to carbapenems. Full Text available with Trip Pro

Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF and ompC in Enterobacter cloacae that are highly resistant to carbapenems. InEnterobacter cloacae, the genetic lesions associated with derepression of the AmpC β-lactamase include diverse single nucleotide polymorphisms (SNPs) and/or indels in theampDandampRgenes and SNPs inampC, while diverse SNPs in the promoter region or SNPs/indels within (...) the coding sequence of outer membrane proteins have been described to alter porin production leading to carbapenem resistance. We sought to define the underlying mechanisms conferring cephalosporin and carbapenem resistance in a collection ofE. cloacaeisolates with unusually high carbapenem resistance and no known carbapenemase and, in contrast to many previous studies, considered the SNPs we detected in relation to the multilocus sequence type (MLST)-based phylogeny of our collection. Whole-genome

2016 Antimicrobial Agents and Chemotherapy

158. Decline in Decreased Cephalosporin Susceptibility and Increase in Azithromycin Resistance in Neisseria gonorrhoeae, Canada. Full Text available with Trip Pro

Decline in Decreased Cephalosporin Susceptibility and Increase in Azithromycin Resistance in Neisseria gonorrhoeae, Canada. Antimicrobial resistance profiles were determined for Neisseria gonorrhoeae strains isolated in Canada during 2010-2014. The proportion of isolates with decreased susceptibility to cephalosporins declined significantly between 2011 and 2014, whereas azithromycin resistance increased significantly during that period. Continued surveillance of antimicrobial drug

2016 Emerging Infectious Diseases

159. Cephalosporin-3' -diazeniumdiolate NO-donor prodrug PYRRO-C3D enhances azithromycin susceptibility of Non-typeable Haemophilus influenzae biofilms. Full Text available with Trip Pro

Cephalosporin-3' -diazeniumdiolate NO-donor prodrug PYRRO-C3D enhances azithromycin susceptibility of Non-typeable Haemophilus influenzae biofilms. PYRRO-C3D is a cephalosporin-3-diazeniumdiolate nitric oxide (NO) donor prodrug designed to selectively deliver NO to bacterial infection sites. The objective of this study was to assess the activity of PYRRO-C3D against nontypeable Haemophilus influenzae (NTHi) biofilms and examine the role of NO in reducing biofilm-associated antibiotic tolerance

2016 Antimicrobial Agents and Chemotherapy

160. Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-onset Bacteremia in Comparison with Third-generation Cephalosporin Therapy. Full Text available with Trip Pro

Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-onset Bacteremia in Comparison with Third-generation Cephalosporin Therapy. Both fluoroquinolones (FQs) and third-generation cephalosporins (3rd-GCs) are commonly prescribed to treat bloodstream infections, but comparative efficacies between them were rarely studied. Demographics and clinical characteristics of 733 adults with polymicrobial or monomicrobial community-onset bacteremia empirically treated

2016 Antimicrobial Agents and Chemotherapy

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>